Paper Review Records
All Paper Review Records
1 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
74
days
Sanguinarine Suppresses Lung Adenocarcinoma via TGF-β1/Smad3 Path way: Insights from Network Analysis and Experimental Validation
Authors
Rong Yuan; Xiaona Li; Junqi Wang; Zhaojun Xu; Lan SongShow moreShow less
Affiliations
1. Medicine School, Hunan University of Chinese Medicine, 300 Xueshi Road, Hanpu Science and Teaching Park, Changsha, Hunan, 410208 , China ;; 2. Hunan Provincial Key Laboratory of Vascular Biology and Translational Medicine, 300 Xueshi Road, Hanpu Science and Teaching Park, Changsha, Hunan, 410208 , China ;; 3. Hebei Yuzhilin Biotechnology Co., Ltd., No. 168 Haidian Road, Shijiazhuang, Hebei, 050035 , China ;; 4. Cardiothoracic Surgery of the First Affiliated Hospital, Hunan University of Chinese Medicine, 97 Shaoshan Road, Changsha, Hunan, 410007 , ChinaShow moreShow less
FAQ
How long does CURRENT PHARMACEUTICAL DESIGN take to review a manuscript?
As of 2026-11-19, CrushSCI has only 1 complete review record for CURRENT PHARMACEUTICAL DESIGN: Sanguinarine Suppresses Lung Adenocarcinoma via TGF-β1/Smad3 Path way: Insights from Network Analysis and Experimental Validation, received 2025-05-15 and accepted 2025-07-28, a review time of 74 days. With a single record, treat this as indicative only.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
